New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
08:02 EDTLGNDLigand announces presentation of data from Phase 1 study
Ligand Pharmaceuticals announced that data from a Phase 1 study of the selective estrogen receptor modulator lasofoxifene were featured in a poster presentation today at ICE/ENDO 2014 in Chicago. The presentation provided data from a first-in-human clinical study of lasofoxifene that was performed by Pfizer and recently analyzed by Ligand demonstrating the potent and prolonged effect of a single dose to increase circulating testosterone and gonadotropin levels in healthy young men. Highlights of the presentation include: In an investigator-blinded, randomized, placebo-controlled, single-ascending dose study involving 36 healthy male volunteers, lasofoxifene was well-absorbed after oral administration with peak plasma concentrations reached approximately 6 to 9 hours post-dose and a long elimination half-life of approximately 106 hours; There were no serious adverse events and no clinically significant changes in safety laboratory, vital signs or ECG assessments; Single oral doses of lasofoxifene of 1, 3, 10, 30 and 100 mg increased levels of testosterone; doses of 30 and 100 mg increased levels of T by more than 80%; Levels of luteinizing hormone and follicle-stimulating hormone were also elevated with single oral doses of 30 and 100 mg; Levels of T, LH and FSH peaked between 3 and 7 days post-dose and elevations induced by higher doses were maintained through at least 28 days; T levels plateaued at the high normal range of 30-40 nmol/L between 7 and 28 days post-dose regardless of lasofoxifene dose or LH levels.
News For LGND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 11, 2015
11:31 EDTLGNDLigand price target raised to $127 from $116 at Roth Capital
Roth Capital raised its price target for Ligand Pharmaceuticals to $127 citing pipeline expansion following the company's Q1 results. Roth recommends "steady accumulation" of the stock and keeps a Buy rating on the name.
08:35 EDTLGNDLigand sees Q2 adjusted EPS 37c-40c, consensus 35c
Subscribe for More Information
08:34 EDTLGNDLigand affirms FY15 adjusted EPS view $2.14-$2.18, consensus $2.13
Subscribe for More Information
08:34 EDTLGNDLigand reports Q1 adjusted EPS 33c, consensus 27c
Reports Q1 revenue $14.6M, consensus $13.53M.
08:16 EDTLGNDLigand acquires rights to over 15 fully-funded development programs from Selexis
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use